Appendix A
Venture-funded Firms Among the 200 Most Prolific Winners of NIH Phase II Awards 1992-2002



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 71
Appendix A Venture-funded Firms Among the 200 Most Prolific Winners of NIH Phase II Awards 1992-2002 71

OCR for page 71
72 APPENDIX A Phase II Awards First Start of Number of Phase II Latest NIH Phase II Company Name Funded Phase II Awards Aastrom Biosciences, Inc. 2/1/1993 3/1/1999 5 Abiomed, Inc. 3/1/1990 9/30/2000 13 Ambion, Inc. 1/1/1993 9/1/2001 8 Biomedical Development Corporation 5/1/1992 9/1/2000 9 Cambridge Neuroscience, Inc. 9/27/1989 9/30/1997 3 Cengent Therapeutics, Inc. 4/1/1999 9/1/1999 3 Centaur Pharmaceuticals, Inc. 2/1/1994 9/30/1996 4 Conductus, Inc. 4/15/1994 6/15/1994 3 Corixa Corporation 9/15/1994 9/1/2000 8 Cortechs Labs, Inc. 5/1/1998 6/15/2002 5 Cubist Pharmaceuticals, Inc. 4/1/1995 4/1/1999 4 Cytel 4/15/1994 7/20/2001 5 Diversa 9/30/1996 11/1/1997 4 EKOS Corporation 6/1/1998 12/1/2000 4 Electro-Optical Sciences, Inc. 6/23/1993 4/19/2001 4 Epoch Biosciences 9/1/1990 1/1/1999 4 Exocell, Inc. 7/1/1992 7/1/2003 6 Foster Miller 5/1/1990 4/15/2001 10 Genaissance Pharmaceuticals, Inc. 9/1/1993 8/29/1997 4 GenPharm International, Inc. 4/1/1991 5/1/1992 4 Gliatech, Inc. 2/24/1995 9/15/1998 3 Hawaii Biotech, Inc. 7/1/1991 2/15/1999 7 IDEC Pharmaceuticals Corporation 8/15/1991 9/30/1997 3 Illumina, Inc. 2/1/1999 7/1/2000 5 Immusol, Inc. 9/30/1996 9/1/1999 4 Inotek Pharmaceuticals Corporation 3/1/1998 8/1/2001 14 Invitrogen Corporation 9/1/1995 9/30/1998 4 Isis Pharmaceuticals 9/1/1991 3/1/1999 4 Martek Biosciences Corporation 9/30/1991 9/30/1995 3 Medical Physics Colorado 5/1/1990 2/15/1992 4 Medimmune, Inc. 3/1/1992 5/1/1996 3 Meridian Instruments, Inc. 2/1/1991 5/1/1993 3 Micronix Corporation 8/1/1992 3/1/2001 6 Neurocrine Biosciences, Inc. 9/30/1994 1/1/2001 8 Nimbus Medical, Inc. 9/1/1990 2/1/1995 4 OSI Pharmaceuticals, Inc. 5/1/1990 2/1/1997 10 Photon Imaging Corporation 4/1/1995 7/1/2001 7 Physical Optics Corporation 2/15/1993 9/30/2001 10 Physical Sciences, Inc. 3/1/1990 3/15/2003 11 Progenics Pharmaceuticals, Inc. 9/1/1991 9/30/1996 5 RiboGene, Inc. 8/1/1994 9/30/1996 4 Scios Nova, Inc. 1/5/1992 11/1/1997 4 Spencer Technologies 9/1/1992 8/1/2000 4 Spire Corporation 9/25/1989 2/15/2002 8 State of The Art, Inc. 8/23/1993 9/14/2000 8

OCR for page 71
73 APPENDIX A All Awards VC Funding Total SBIR Most Recent Number of Funding 1st Round Round Rounds Total VC Funding 4,905,444 8/18/1989 10/30/2002 8 36,385,000 8,924,132 12/1/1984 12/1/1984 1 3,000,000 8,566,387 5/1/2003 5/1/2003 1 10,500,000 6,967,861 10/1/1987 10/1/1987 1 150,000 2,267,025 1/1/1986 6/21/1997 9 35,879,000 2,647,188 1/11/1996 11/30/2000 5 47,350,000 3,989,316 12/1/1992 11/2/2001 7 26,561,000 2,904,807 9/1/1987 3/27/2002 6 45,700,000 7,971,063 12/2/1994 10/2/1997 3 59,330,000 3,793,553 1/9/1987 11/23/1992 4 51,000,000 4,758,137 9/1/1992 9/23/1998 5 36,283,000 4,026,867 8/1/1987 11/22/1991 4 68,000,000 4,228,546 12/1/1994 2/14/2000 5 210,200,000 3,350,438 10/1/1996 8/30/2001 5 42,900,000 3,262,764 1/15/1986 6/20/2003 8 32,440,000 3,238,220 3/1/1986 7/1/1993 13 29,980,000 4,352,150 3/1/1988 3/1/1988 1 900,000 11,827,620 1/1/1980 1/1/1980 1 750,000 3,581,611 4/1/1998 5/22/2000 7 73,522,000 1,748,679 12/3/1988 4/1/1995 9 40,100,000 3,342,616 7/1/1988 6/1/1995 7 32,596,000 9,643,061 6/7/2002 6/6/2003 2 7,300,000 2,441,576 5/1/1986 2/1/1990 4 43,870,000 5,715,123 11/30/1998 11/1/1999 2 36,567,000 3,347,984 6/1/2001 9/24/2003 2 23,500,000 29,421,600 3/31/2004 3/31/2004 1 20,000,000 4,254,170 6/20/1997 6/20/1997 1 15,000,000 3,210,263 2/1/1989 8/11/1994 6 17,490,000 3,220,694 1/15/1986 11/23/1993 5 22,750,000 2,698,149 12/30/1991 12/30/1991 1 20,000 2,912,945 5/1/1988 12/9/1991 5 143,850,000 1,746,413 5/1/1983 10/1/1993 4 3,557,000 4,264,334 5/1/1981 7/1/1987 15 76,598,000 10,349,174 9/25/1992 5/23/1996 12 43,000,000 3,147,990 7/1/1986 3/1/1987 2 5,598,000 8,563,722 3/1/1988 3/1/1988 1 4,000,000 7,889,307 9/1/1983 9/1/1983 1 750,000 9,782,753 8/1/1987 8/1/1990 4 3,337,000 8,175,374 5/9/1995 7/1/1995 2 492,000 14,190,507 1/1/1995 12/1/1995 1 5,670,000 3,727,127 1/1/1990 2/1/1997 14 43,577,000 2,704,476 6/1/1982 6/1/1982 1 5,425,000 3,334,165 7/1/1997 7/1/1997 1 435,000 7,514,150 11/1/1979 1/1/1987 3 3,750,000 8,231,063 9/1/1983 1/1/1986 2 3,400,000 continued

OCR for page 71
7 APPENDIX A Phase II Awards First Start of Number of Phase II Latest NIH Phase II Company Name Funded Phase II Awards Stratagene Cloning Systems 7/1/1991 4/7/1997 6 Talaria Holdings, LLC 7/12/1996 7/1/2001 8 Third Wave Technologies, Inc. 4/1/1993 9/25/2001 5 Transoma Medical, Inc. 4/1/1996 8/1/1999 3 Valentis 3/26/1993 3/1/1997 4 Volumetrics Medical Imaging 8/1/1993 6/1/2000 3 Total 285 Legend 34 First VC funding before first SBIR Phase II 17 Last VC funding after start of latest SBIR Phase II 6 First VC funding after last start date for SBIR Phase II 51 Total VC-funded companies identified as NIH SBIR Top 200 SOURCE: Award data: National Institutes of Health data delivered to the National Research Council; VC data: Thomson Financial, VentureSource, and RDNA databases.

OCR for page 71
7 APPENDIX A All Awards VC Funding Total SBIR Most Recent Number of Funding 1st Round Round Rounds Total VC Funding 4,754,214 4/1/1987 12/31/1992 2 1,873,000 7,068,657 1/1/2001 4/1/2001 2 28,673,000 3,778,257 6/30/1995 7/26/2000 5 78,064,000 3,384,761 2/5/2002 2/5/2002 1 12,075,000 3,350,068 8/12/1993 10/1/2002 6 47,405,000 2,432,255 1/1/1995 6/27/2003 6 10,706,000 272,332,457 224 1,592,258,000